Who are Casgevy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Exa-cel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exagamglogene-autotemcel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Casgevy — Competitive Intelligence Brief

Casgevy (EXAGAMGLOGENE AUTOTEMCEL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous genome-edited hematopoietic stem cell therapy.

marketed Autologous genome-edited hematopoietic stem cell therapy BCL11A Gene therapy Live · refreshed every 30 min

Target snapshot

Casgevy (EXAGAMGLOGENE AUTOTEMCEL). Edited CD34+ cells with reduced BCL11A expression increase γ-globin and HbF production, preventing sickling and transfusion dependence.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Casgevy TARGET	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Exa-cel	Exa-cel	Vertex Pharmaceuticals Incorporated	phase 3	CRISPR gene-editing therapy	BCL11A gene

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous genome-edited hematopoietic stem cell therapy class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Casgevy — Competitive Intelligence Brief. https://druglandscape.com/ci/exagamglogene-autotemcel. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab